CSL Makes $11.7bn Move On Vifor Pharma In Renal Disease Push
Confirming rumors of an acquisition, CSL will venture into some new territories as well as boost its renal franchise when it takes over Switzerland’s Vifor Pharma in a deal worth $11.7bn.
You may also be interested in...
Teva has been shot down in its attempts to circumvent a key US patent shielding Vifor Pharma’s Velphoro dialysis drug.
Based on top-line Phase III data for garadacimab, CSL is preparing to submit the Factor XIIa inhibitor for US FDA approval for monthly prophylaxis of hereditary angioedema and expand the firm’s HAE franchise.
Rising leader Mårten Steen, spoke with In Vivo about translating science into business, building precision medicine firms from the ground up and the importance of high-energy leadership.